Loestrin Ruling Signals Non-Cash Deals Won't Evade Actavis
With its ruling Monday that Warner Chilcott's noncash settlements with generics makers over its contraceptive Loestrin could face antitrust scrutiny, the First Circuit fell into line with other courts and brought...To view the full article, register now.
Already a subscriber? Click here to view full article